Topographic maps of difference in theta power between breathing conditions. by Anita B. Frohlich (20660615)

Subjects:

Primary data. by Andrey V. Cybulsky (4007012)

Subjects:

Original data2. by Lan Zeng (638254)

Subjects:

Original data1. by Lan Zeng (638254)

Subjects:

Variations in slope utilization by a female red panda across different time periods and in comparison with their wild individuals. Different capital letters indicated significant d... by Yanshan Zhou (14131359)

Subjects:

Variations in altitude utilization by a female red panda across different time periods and in comparison with wild individuals. Different capital letters indicated significant diff... by Yanshan Zhou (14131359)

Subjects:

Variations in aspect utilization by a female red panda across different time periods and in comparison with wild individuals. Different capital letters indicated significant differ... by Yanshan Zhou (14131359)

Subjects:

Demographic information. by Silas Manning (22693338)

Subjects:

Characteristics of JIA patients. by Yasmine Makhlouf (17409866)

Subjects:

List of excluded articles. by Yasmine Makhlouf (17409866)

Subjects:

S1 File - by Michael Gulledge (20577135)

Subjects:

Results for the asymmetric relationship between military expenditures and DOD energy consumption. by Ryan P. Thombs (9138968)

Subjects:

Coefficient plot of short-run effects. by Ryan P. Thombs (9138968)

Subjects:

Seven forecast scenarios. by Ryan P. Thombs (9138968)

Subjects:

Annual Difference in Energy Consumption Relative to Historical Median Change by 2032. by Ryan P. Thombs (9138968)

Subjects:

Coefficient plot of long-run effects. by Ryan P. Thombs (9138968)

Subjects:

Results for the asymmetric relationship between military expenditures and DOD energy consumption. by Ryan P. Thombs (9138968)

Subjects:

Time series of military expenditures and DOD energy consumption. by Ryan P. Thombs (9138968)

Subjects:

Forecast for each scenario, 2023-2032. by Ryan P. Thombs (9138968)

Subjects:

Reversible Small Molecule Multivariant Ras Inhibitors Display Tunable Affinity for the Active and Inactive Forms of Ras by Charles W. Parry (20966154)

“…Activating mutations of Ras are one of the most prevalent drivers of cancer and are often associated with poor clinical outcomes. Despite FDA approval for two irreversible inhibitors that target the inactive state of KRas^G12C, significant unmet clinical need still exists, and the susceptibility of non-G12C mutants to inactive-state inhibition remains unclear. …”